Koers Nascent Biotech, Inc. Other OTC
Aandelen
NBIO
US63108Q1013
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 1 0,93 | Omzet 2023 | - | Marktkapitalisatie | 7,16 mln. 6,66 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | - 0 | Nettowinst (verlies) 2023 | -2 mln. -1,86 mln. | EV/omzet 2022 | 6.213.671 x |
Nettoliquiditeiten 2022 | 94,41K 87,74K | Nettoschuld 2023 | 217K 202K | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-13,1
x | K/w-verhouding 2023 |
-2,38
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 60% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sean Carrick
CEO | Chief Executive Officer | 56 | 15-07-14 |
Lowell Holden
DFI | Director of Finance/CFO | 82 | 15-07-14 |
Douglas Karas
BRD | Director/Board Member | 59 | 04-04-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lowell Holden
DFI | Director of Finance/CFO | 82 | 15-07-14 |
Sean Carrick
CEO | Chief Executive Officer | 56 | 15-07-14 |
Douglas Karas
BRD | Director/Board Member | 59 | 04-04-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,43% | 103 mld. | |
+8,96% | 101 mld. | |
+4,40% | 23,07 mld. | |
-12,15% | 22,23 mld. | |
-4,36% | 18,05 mld. | |
-39,98% | 17,18 mld. | |
-10,04% | 16,94 mld. | |
+6,79% | 14,07 mld. | |
+38,61% | 12,35 mld. |